Brief: OraSure Technologies Q2 Revenue USD 31.2 Million

OraSure Technologies

05/08/2025 21:05

Overview

OraSure Q2 2025 revenue falls 43% yr/yr, beats analyst expectations, per LSEG data

Adjusted operating income for Q2 beats analyst expectations, per LSEG data

Co repurchased 1.8 mln shares during Q2

Outlook

OraSure expects Q3 2025 revenue of $27 mln to $30 mln

Result Drivers

COVID-19 REVENUE DECLINE - Significant drop in COVID-19 related revenues contributed to overall revenue decline

PRODUCT PORTFOLIO EXPANSION - Launch of new blood collection device for proteomic research expected to drive future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$31.20 mln
$30.40 mln (3 Analysts)
Q2 Gross Margin
42.1%
Q2 Adjusted Operating Income
Beat
-$13.20 mln
-$17.40 mln (1 Analyst)
Q2 Operating Income
-$18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OraSure Technologies Inc is $6.00, about 48% above its August 4 closing price of $3.12

Press Release: ID:nGNX5sYlZY

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)